The effect of lenvatinib in combination with chemotherapy plus immune checkpoint inhibitors on tumor microenvironments in the mouse syngeneic tumor model

被引：0
|
作者：
Kato, Yu
Ozawa, Yoichi
Adachi, Keito
Kume, Masahiko
Adachi, Yusuke
Narita, Yudai
Kuronishi, Megumi
Matsui, Junji
Yokoi, Akira
Funahashi, Yasuhiro
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5124
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors
    Muraro, Elena
    Vinante, Lorenzo
    Fratta, Elisabetta
    Bearz, Alessandra
    Hoefler, Daniela
    Steffan, Agostino
    Baboci, Lorena
    CANCERS, 2023, 15 (09)
  • [2] ARMED MYXOMA VIRUS DEMONSTRATES EFFICACY IN SYNGENEIC TUMOR MODELS ALONE AND IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS
    Franco, Lina
    Torres-Dominguez, Lino
    Mamola, Joseph
    de Matos, Ana
    Abrantes, Mario
    Walker, Benjamin
    Tacner, Zachary
    Kien, Cassandra
    Elliott, Natalie
    McFadden, Grant
    Sharp, Leslie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A356 - A356
  • [3] Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumor mouse models
    Rolland, S.
    Klinz, S. G.
    Meyer-Losic, F.
    Nahkle, J.
    Delille, R.
    de Boisferon, M. Hillairet
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Immune regulation of tumor dormancy in syngeneic mouse model
    Piranlioglu, Raziye
    Ouzounova, Maria
    Lee, Eunmi
    Hudson, Alicia
    Korkaya, Sumeyye
    Arbab, Ali
    Korkaya, Hasan
    CANCER RESEARCH, 2016, 76
  • [5] Armed Myxoma virus demonstrates efficacy in syngeneic tumor models alone and in combination with immune checkpoint inhibitors.
    Franco, Lina S.
    Torres-Dominguez, Lino E.
    Mamola, Joseph
    de Matos, Ana L.
    Abrantes, Mario
    Walker, Benjamin S.
    Tacner, Zachary
    Kien, Cassandra
    Elliott, Natalie M.
    McFadden, Grant
    Sharp, Leslie L.
    CANCER IMMUNOLOGY RESEARCH, 2021, 9 (02)
  • [6] Site specific tumor response to combination chemotherapy and immune checkpoint inhibitor in the syngeneic Pan02 pancreatic ductal adenocarcinoma model
    Wong, Andrew
    Fadden, Patrick
    Clouse, Cara
    Wood, Patrick
    Brown-Augustine, Marianna
    Zhao, Fei
    Ser, Elliot
    Kolb, Joseph
    Hall, Chassidy
    Rainbolt, Elizabeth
    CANCER RESEARCH, 2023, 83 (07)
  • [7] Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model
    Ghosh, Sanjana
    He, Xuedan
    Huang, Wei-Chiao
    Lovell, Jonathan F. F.
    APL BIOENGINEERING, 2022, 6 (03)
  • [8] Characterizing the effect of immune checkpoint inhibitors on syngeneic tumor models through gut mircrobiome sequencing and immune-phenotyping
    Maves, Y. Kato
    Izadi, H.
    Calinisan, A.
    Talaoc, C.
    Yan, D.
    Echegaray, C.
    Blair, M.
    Mizukoshi, R.
    Thatte, J.
    Broudy, T.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S111 - S111
  • [9] Efficacy of ALKS 4230, a novel immunotherapeutic agent, in murine syngeneic tumor models alone and in combination with immune checkpoint inhibitors
    Losey, Heather C.
    Lopes, Jared E.
    Dean, Reginald L.
    Huff, Michael R.
    Moroso, Rosemarie A.
    Alvarez, Juan C.
    CANCER RESEARCH, 2017, 77
  • [10] Armed oncolytic myxoma virus demonstrates efficacy in syngeneic tumor models alone and in combination with immune checkpoint inhibitors.
    Franco, Lina S.
    Mamola, Joseph
    Abdullahi, Wazir
    De Matos, Ana
    Abrantes, Mario
    Walker, Benjamin S.
    Tacner, Zachary
    Grigaitis, Nicole
    Kien, Cassandra
    McFadden, Grant
    Sharp, Leslie L.
    CANCER RESEARCH, 2021, 81 (13)
12345